Global Competent Cells Market Size, Share & Trends Analysis Report By Type, By Application (Cloning, Protein Expression, Mutagenesis, and Others), By End-Use, By Regional Outlook and Forecast, 2024 - 2031

Global Competent Cells Market Size, Share & Trends Analysis Report By Type, By Application (Cloning, Protein Expression, Mutagenesis, and Others), By End-Use, By Regional Outlook and Forecast, 2024 - 2031


The Global Competent Cells Market size is expected to reach $3.7 billion by 2031, rising at a market growth of 7.9% CAGR during the forecast period.

Rising healthcare expenditures in Asia Pacific countries fuel demand for innovative biopharmaceuticals, personalized medicine, and diagnostic tools. These cells are essential in developing these healthcare solutions, contributing to market growth. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.

Recombinant DNA technology is fundamental for cloning and expressing genes in host cells. These cells are essential for introducing recombinant DNA into bacterial cells to produce therapeutic proteins, enzymes, and vaccines. In addition, the development of personalized medicine, which tailors’ treatments based on individual genetic profiles, relies on recombinant DNA technology and these cells. Hence, the growing demand for recombinant DNA technology drives the market's growth.

Additionally, these cells are essential for introducing and expressing genes of interest to study their functions. Researchers use these cells to clone specific genes, manipulate DNA sequences, and explore gene interactions, which are fundamental in understanding biological processes and disease mechanisms. Thus, the expansion of genomic and proteomic studies is propelling the market's growth.

Moreover, the pandemic spurred heightened demand for these cells as pharmaceutical and biotech companies accelerated research and development efforts for vaccines and therapies. Also, companies in the competent cells sector adapted quickly to ensure uninterrupted supply chains, enhancing market stability and growth during the pandemic. Thus, the COVID-19 pandemic had a positive impact on the market.

However, establishing a competent cell production facility requires significant investment in specialized equipment such as bioreactors, incubators, purification systems, and sterile facilities. Moreover, scaling up production from laboratory-scale to commercial quantities can involve additional costs related to process optimization, validation, and facility expansion. Hence, high initial costs are hindering the growth of the market.

Type Outlook

Based on type, the market is divided into chemically competent cells, electrocompetent cells, and ultracompetent cells. The electrocompetent cells segment attained 34% revenue share in the market in 2023. Electrocompetent cells typically offer higher transformation efficiencies compared to chemically competent cells. This makes them suitable for applications that require precise control over transformation efficiency, such as gene editing, library construction, and high-throughput screening.

Application Outlook

On the basis of application, the market is segmented into cloning, protein expression, mutagenesis, and others. In 2023, the protein expression segment attained a 24% revenue share in the market. These cells with high transformation efficiencies and robust protein expression capabilities are preferred for generating large quantities of recombinant proteins.

End-Use Outlook

By end-use, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and others. The academic & research institutes segment procured a 37% revenue share in the market in 2023. These cells are fundamental tools in molecular biology research for studying gene function, protein expression, and genetic pathways. Academic institutions use these cells to conduct basic research that advances our understanding of biological processes and diseases.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 35% revenue share in the market in 2023. North America hosts some of the world’s leading biotechnology and pharmaceutical companies, particularly the United States and Canada. These industries drive substantial demand for these cells for research, development, and production of biopharmaceuticals, vaccines, and therapeutic proteins.

Recent Strategies Deployed in the Market
  • Jun-2024: Thermo Fisher Scientific established a new manufacturing practice (cGMP) facility in Bleiswijk, Netherlands, bolstering its European clinical trial capabilities for advanced therapies. The site offers comprehensive support for cell and gene therapies, emphasizing sustainable operations towards achieving net-zero emissions by 2050.
  • May-2024: Thermo Fisher Scientific launched the Applied Biosystems Axiom BloodGenomiX Array, designed for accurate blood genotyping in clinical research. This innovative platform covers over 40 genes and more than 260 antigens, detecting both HLA and HPA types with an impressive concordance rate of 99.89%.
  • Dec-2022: Agilent's Resolution ctDx FIRST has received FDA approval as a companion diagnostic for KRAS G12C mutations in advanced non-small cell lung cancer (NSCLC), facilitating treatment decisions for patients eligible for KRAZATI (adagrasib). Developed with Mirati Therapeutics, this liquid biopsy NGS assay offers broad genomic profiling for NSCLC patients.
  • Sep-2023: Thermo Fisher Scientific and the National Minority Quality Forum are partnering through ARC to improve access to clinical research for historically underserved communities. The collaboration aims to promote diversity in trials and facilitate equitable healthcare access initiatives.
  • Sep-2023: Thermo Fisher Scientific introduces the TSX Universal Series ULT Freezers, featuring enhanced performance, energy efficiency, and adaptability across lab settings. Certified by ENERGY STAR® and designed for sustainability, these freezers support diverse scientific workflows and stringent quality standards.
List of Key Companies Profiled
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Promega Corporation
  • New England Biolabs, Inc.
  • Qiagen N.V
  • F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc. (Takara Holdings Inc.)
  • Lonza Group Ltd. (Capsugel)
Global Competent Cells Market Report Segmentation

By Type
  • Chemically Competent Cells
  • Electrocompetent Cells
  • Ultracompetent Cells
By Application
  • Cloning
  • Protein Expression
  • Mutagenesis
  • Others
By End-Use
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Competent Cells Market, by Type
1.4.2 Global Competent Cells Market, by Application
1.4.3 Global Competent Cells Market, by End-Use
1.4.4 Global Competent Cells Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Competent Cells Market
Chapter 5. Global Competent Cells Market by Type
5.1 Global Chemically Competent Cells Market by Region
5.2 Global Electrocompetent Cells Market by Region
5.3 Global Ultracompetent Cells Market by Region
Chapter 6. Global Competent Cells Market by Application
6.1 Global Cloning Market by Region
6.2 Global Protein Expression Market by Region
6.3 Global Mutagenesis Market by Region
6.4 Global Others Market by Region
Chapter 7. Global Competent Cells Market by End-Use
7.1 Global Pharmaceutical & Biotechnology Companies Market by Region
7.2 Global Academic & Research Institutes Market by Region
7.3 Global Others Market by Region
Chapter 8. Global Competent Cells Market by Region
8.1 North America Competent Cells Market
8.1.1 North America Competent Cells Market by Type
8.1.1.1 North America Chemically Competent Cells Market by Country
8.1.1.2 North America Electrocompetent Cells Market by Country
8.1.1.3 North America Ultracompetent Cells Market by Country
8.1.2 North America Competent Cells Market by Application
8.1.2.1 North America Cloning Market by Country
8.1.2.2 North America Protein Expression Market by Country
8.1.2.3 North America Mutagenesis Market by Country
8.1.2.4 North America Others Market by Country
8.1.3 North America Competent Cells Market by End-Use
8.1.3.1 North America Pharmaceutical & Biotechnology Companies Market by Country
8.1.3.2 North America Academic & Research Institutes Market by Country
8.1.3.3 North America Others Market by Country
8.1.4 North America Competent Cells Market by Country
8.1.4.1 US Competent Cells Market
8.1.4.1.1 US Competent Cells Market by Type
8.1.4.1.2 US Competent Cells Market by Application
8.1.4.1.3 US Competent Cells Market by End-Use
8.1.4.2 Canada Competent Cells Market
8.1.4.2.1 Canada Competent Cells Market by Type
8.1.4.2.2 Canada Competent Cells Market by Application
8.1.4.2.3 Canada Competent Cells Market by End-Use
8.1.4.3 Mexico Competent Cells Market
8.1.4.3.1 Mexico Competent Cells Market by Type
8.1.4.3.2 Mexico Competent Cells Market by Application
8.1.4.3.3 Mexico Competent Cells Market by End-Use
8.1.4.4 Rest of North America Competent Cells Market
8.1.4.4.1 Rest of North America Competent Cells Market by Type
8.1.4.4.2 Rest of North America Competent Cells Market by Application
8.1.4.4.3 Rest of North America Competent Cells Market by End-Use
8.2 Europe Competent Cells Market
8.2.1 Europe Competent Cells Market by Type
8.2.1.1 Europe Chemically Competent Cells Market by Country
8.2.1.2 Europe Electrocompetent Cells Market by Country
8.2.1.3 Europe Ultracompetent Cells Market by Country
8.2.2 Europe Competent Cells Market by Application
8.2.2.1 Europe Cloning Market by Country
8.2.2.2 Europe Protein Expression Market by Country
8.2.2.3 Europe Mutagenesis Market by Country
8.2.2.4 Europe Others Market by Country
8.2.3 Europe Competent Cells Market by End-Use
8.2.3.1 Europe Pharmaceutical & Biotechnology Companies Market by Country
8.2.3.2 Europe Academic & Research Institutes Market by Country
8.2.3.3 Europe Others Market by Country
8.2.4 Europe Competent Cells Market by Country
8.2.4.1 Germany Competent Cells Market
8.2.4.1.1 Germany Competent Cells Market by Type
8.2.4.1.2 Germany Competent Cells Market by Application
8.2.4.1.3 Germany Competent Cells Market by End-Use
8.2.4.2 UK Competent Cells Market
8.2.4.2.1 UK Competent Cells Market by Type
8.2.4.2.2 UK Competent Cells Market by Application
8.2.4.2.3 UK Competent Cells Market by End-Use
8.2.4.3 France Competent Cells Market
8.2.4.3.1 France Competent Cells Market by Type
8.2.4.3.2 France Competent Cells Market by Application
8.2.4.3.3 France Competent Cells Market by End-Use
8.2.4.4 Russia Competent Cells Market
8.2.4.4.1 Russia Competent Cells Market by Type
8.2.4.4.2 Russia Competent Cells Market by Application
8.2.4.4.3 Russia Competent Cells Market by End-Use
8.2.4.5 Spain Competent Cells Market
8.2.4.5.1 Spain Competent Cells Market by Type
8.2.4.5.2 Spain Competent Cells Market by Application
8.2.4.5.3 Spain Competent Cells Market by End-Use
8.2.4.6 Italy Competent Cells Market
8.2.4.6.1 Italy Competent Cells Market by Type
8.2.4.6.2 Italy Competent Cells Market by Application
8.2.4.6.3 Italy Competent Cells Market by End-Use
8.2.4.7 Rest of Europe Competent Cells Market
8.2.4.7.1 Rest of Europe Competent Cells Market by Type
8.2.4.7.2 Rest of Europe Competent Cells Market by Application
8.2.4.7.3 Rest of Europe Competent Cells Market by End-Use
8.3 Asia Pacific Competent Cells Market
8.3.1 Asia Pacific Competent Cells Market by Type
8.3.1.1 Asia Pacific Chemically Competent Cells Market by Country
8.3.1.2 Asia Pacific Electrocompetent Cells Market by Country
8.3.1.3 Asia Pacific Ultracompetent Cells Market by Country
8.3.2 Asia Pacific Competent Cells Market by Application
8.3.2.1 Asia Pacific Cloning Market by Country
8.3.2.2 Asia Pacific Protein Expression Market by Country
8.3.2.3 Asia Pacific Mutagenesis Market by Country
8.3.2.4 Asia Pacific Others Market by Country
8.3.3 Asia Pacific Competent Cells Market by End-Use
8.3.3.1 Asia Pacific Pharmaceutical & Biotechnology Companies Market by Country
8.3.3.2 Asia Pacific Academic & Research Institutes Market by Country
8.3.3.3 Asia Pacific Others Market by Country
8.3.4 Asia Pacific Competent Cells Market by Country
8.3.4.1 China Competent Cells Market
8.3.4.1.1 China Competent Cells Market by Type
8.3.4.1.2 China Competent Cells Market by Application
8.3.4.1.3 China Competent Cells Market by End-Use
8.3.4.2 Japan Competent Cells Market
8.3.4.2.1 Japan Competent Cells Market by Type
8.3.4.2.2 Japan Competent Cells Market by Application
8.3.4.2.3 Japan Competent Cells Market by End-Use
8.3.4.3 India Competent Cells Market
8.3.4.3.1 India Competent Cells Market by Type
8.3.4.3.2 India Competent Cells Market by Application
8.3.4.3.3 India Competent Cells Market by End-Use
8.3.4.4 South Korea Competent Cells Market
8.3.4.4.1 South Korea Competent Cells Market by Type
8.3.4.4.2 South Korea Competent Cells Market by Application
8.3.4.4.3 South Korea Competent Cells Market by End-Use
8.3.4.5 Australia Competent Cells Market
8.3.4.5.1 Australia Competent Cells Market by Type
8.3.4.5.2 Australia Competent Cells Market by Application
8.3.4.5.3 Australia Competent Cells Market by End-Use
8.3.4.6 Malaysia Competent Cells Market
8.3.4.6.1 Malaysia Competent Cells Market by Type
8.3.4.6.2 Malaysia Competent Cells Market by Application
8.3.4.6.3 Malaysia Competent Cells Market by End-Use
8.3.4.7 Rest of Asia Pacific Competent Cells Market
8.3.4.7.1 Rest of Asia Pacific Competent Cells Market by Type
8.3.4.7.2 Rest of Asia Pacific Competent Cells Market by Application
8.3.4.7.3 Rest of Asia Pacific Competent Cells Market by End-Use
8.4 LAMEA Competent Cells Market
8.4.1 LAMEA Competent Cells Market by Type
8.4.1.1 LAMEA Chemically Competent Cells Market by Country
8.4.1.2 LAMEA Electrocompetent Cells Market by Country
8.4.1.3 LAMEA Ultracompetent Cells Market by Country
8.4.2 LAMEA Competent Cells Market by Application
8.4.2.1 LAMEA Cloning Market by Country
8.4.2.2 LAMEA Protein Expression Market by Country
8.4.2.3 LAMEA Mutagenesis Market by Country
8.4.2.4 LAMEA Others Market by Country
8.4.3 LAMEA Competent Cells Market by End-Use
8.4.3.1 LAMEA Pharmaceutical & Biotechnology Companies Market by Country
8.4.3.2 LAMEA Academic & Research Institutes Market by Country
8.4.3.3 LAMEA Others Market by Country
8.4.4 LAMEA Competent Cells Market by Country
8.4.4.1 Brazil Competent Cells Market
8.4.4.1.1 Brazil Competent Cells Market by Type
8.4.4.1.2 Brazil Competent Cells Market by Application
8.4.4.1.3 Brazil Competent Cells Market by End-Use
8.4.4.2 Argentina Competent Cells Market
8.4.4.2.1 Argentina Competent Cells Market by Type
8.4.4.2.2 Argentina Competent Cells Market by Application
8.4.4.2.3 Argentina Competent Cells Market by End-Use
8.4.4.3 UAE Competent Cells Market
8.4.4.3.1 UAE Competent Cells Market by Type
8.4.4.3.2 UAE Competent Cells Market by Application
8.4.4.3.3 UAE Competent Cells Market by End-Use
8.4.4.4 Saudi Arabia Competent Cells Market
8.4.4.4.1 Saudi Arabia Competent Cells Market by Type
8.4.4.4.2 Saudi Arabia Competent Cells Market by Application
8.4.4.4.3 Saudi Arabia Competent Cells Market by End-Use
8.4.4.5 South Africa Competent Cells Market
8.4.4.5.1 South Africa Competent Cells Market by Type
8.4.4.5.2 South Africa Competent Cells Market by Application
8.4.4.5.3 South Africa Competent Cells Market by End-Use
8.4.4.6 Nigeria Competent Cells Market
8.4.4.6.1 Nigeria Competent Cells Market by Type
8.4.4.6.2 Nigeria Competent Cells Market by Application
8.4.4.6.3 Nigeria Competent Cells Market by End-Use
8.4.4.7 Rest of LAMEA Competent Cells Market
8.4.4.7.1 Rest of LAMEA Competent Cells Market by Type
8.4.4.7.2 Rest of LAMEA Competent Cells Market by Application
8.4.4.7.3 Rest of LAMEA Competent Cells Market by End-Use
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Product Launches and Product Expansions:
9.1.5.3 Geographical Expansions:
9.1.6 SWOT Analysis
9.2 Merck KGaA
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.6 SWOT Analysis
9.3 Agilent Technologies, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Trail and Approvals:
9.3.6 SWOT Analysis
9.4 Bio-Rad laboratories, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 SWOT Analysis
9.5 Promega Corporation
9.5.1 Company Overview
9.5.2 Recent strategies and developments:
9.5.2.1 Partnerships, Collaborations, and Agreements:
9.5.3 SWOT Analysis
9.6 New England Biolabs, Inc.
9.6.1 Company Overview
9.6.2 SWOT Analysis
9.7 Qiagen N.V.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Takara Bio Inc. (Takara Holdings Inc.)
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expenses
9.10. Lonza Group Ltd. (Capsugel)
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 SWOT Analysis
Chapter 10. Winning Imperatives of Competent Cells Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings